medRxiv preprint doi: https://doi.org/10.1101/2021.11.21.21264927; this version posted November 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

р	reprint (which was not certified by peer review) is the author/funder, who has granted medRXiv a license to display the preprint perpetuity. It is made available under a CC-BY-ND 4.0 International license .
	Development and Evaluation of AccuPower® COVID-19 Multiplex
	Real-Time RT-PCR Kit and AccuPower® SARS-CoV-2 Multiplex
	Real-Time RT-PCR Kit for SARS-CoV-2 Detection in Sputum,
	NPS/OPS, Saliva and Pooled Samples.
	Suh In Bum <sup>1</sup> , Jaegyun Lim <sup>2</sup> , Hyo Seon Kim <sup>3</sup> , Guil Rhim <sup>4</sup> , Kim Heebum <sup>1</sup> , Kim Hana <sup>1</sup> , Lee Sae-Mi <sup>1</sup> , Park Hyun-sang <sup>1</sup> , Song Hyun Ju <sup>1</sup> , Hong MyungKook <sup>1</sup> , Shin Gyung Sook <sup>1</sup> , Moon Jung Kim <sup>2, *</sup>
	<sup>1</sup> Department of Laboratory Medicine, College of Medicine, Kangwon National University, Chuncheon, Korea
	<sup>2</sup> Department of Laboratory Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea
	<sup>3</sup> Research Administration Team, Institute of Clinical Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea
	<sup>4</sup> Department of General Affairs, Korean Association of Otorhinolaryngologists, Seoul, Korea
	*Corresponding author E-mail: kimmunj@gmail.com

## 30 Abstract

> - 1 -NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 Rapid and accurate detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for the successful control of the current global COVID-19 pandemic. 32 The real-time reverse transcription polymerase chain reaction (Real-time RT-PCR) is the most 33 widely used detection technique. This research describes the development of two novel 34 multiplex real-time RT-PCR kits, AccuPower® COVID-19 Multiplex Real-Time RT-PCR Kit 35 (NCVM) specifically designed for use with the ExiStation<sup>TM</sup>48 system (comprised of 36 *ExiPrep*<sup>TM</sup>48 Dx and *Exicvcler*<sup>TM</sup>96 by BIONEER, Korea) for sample RNA extraction and 37 PCR detection, and AccuPower® SARS-CoV-2 Multiplex Real-Time RT-PCR Kit (SCVM) 38 designed to be compatible with manufacturers' on-market PCR instruments. The limit of 39 detection (LoD) of NCVM was 120 copies/µL and the LoD of the SCVM was 2 copies/mL for 40 both the gene and the SARS-CoV-2 gene (N gene and RdRp gene). The AccuPower<sup>®</sup> kits 41 demonstrated high precision with no cross reactivity to other respiratory-related 42 microorganisms. The clinical performance of AccuPower® kits was evaluated using the 43 following clinical samples: sputum and nasopharyngeal/oropharyngeal swab (NPS/OPS) 44 samples. Overall agreement of the AccuPower<sup>®</sup> kits with a Food and Drug Administration 45 (FDA) approved emergency use authorized commercial kit (STANDARD™ M nCoV Real-46 Time Detection kit, SD BIOSENSOR, Korea) was above 95% (Cohen's kappa coefficient  $\geq$ 47 0.95), with a sensitivity of over 95%. The NPS/OPS specimen pooling experiment was 48 conducted to verify the usability of AccuPower<sup>®</sup> kits on pooled samples and the results showed 49 greater than 90% agreement with individual NPS/OPS samples. The clinical performance of 50 AccuPower<sup>®</sup> kits with saliva samples was also compared with NPS/OPS samples and 51 52 demonstrated over 95% agreement (Cohen's kappa coefficient > 0.95). This study shows the BIONEER NCVM and SCVM assays are comparable with the current standard confirmation 53 assay and are suitable for effective clinical management and control of SARS-CoV-2. 54

- 2 -

# Keywords: SARS-CoV-2, COVID-19, Real-Time RT-PCR, Multiplex PCR Kits, diagnostic

## 57 Introduction

Coronavirus disease 2019 (COVID-19) was first detected in Wuhan, China in 2019, and its outbreak has spread to other countries which led to a global pandemic (1). The virus that causes COVID-19 was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the seventh known coronavirus that can infect humans (2). According to World Health Organization (WHO), as of June 30, 2021, approximately 181 million people were confirmed with SARS-CoV-2 infection, and 3.9 million were dead world-wide. (https://covid19.who.int/).

The key strategy for controlling outbreaks of COVID-19 is early and accurate 65 detection of SARS-CoV-2 in the community. Real-time reverse transcription polymerase chain 66 reaction (Real-time RT-PCR) a gold standard method in the detection of various viral diseases, 67 is also the most reliable and accessible method for the diagnosis of SARS-CoV-2 infection (3). 68 SARS-CoV-2 is a positive-sense single-strand RNA virus that consists of RNA-dependent 69 70 RNA polymerase (RdRp) in an ORF1ab (4), envelope, nucleocapsid, spike, and membrane protein. The genes of these regions have been chosen as the target for the detection of SARS-71 CoV-2 (5). RNA viruses have a high tendency for multiple mutations. The mutations in the 72 73 RNA sequence can decrease the detection ratio of the primers and probes, which may lead to the increased false-negative rates. Thus, the primers and probes in this study are designed to 74 target multiple conserved regions to minimize the false negatives caused by mutations. 75

76

Two novel multiplex Real-Time RT-PCR kits, AccuPower® COVID-19 Multiplex

Real-Time RT-PCR Kit (Cat No. NCVM-1111, BIONEER, Korea) and AccuPower® SARS-77 CoV-2 Multiplex Real-Time RT-PCR Kit (Cat No. SCVM-2112, BIONEER, Korea), were used 78 in this study to detect the three viral genes of SARS-CoV-2 (RdRp gene, E gene, and N gene). 79 The NCVM is a premixed product that is specifically designed to be used with the 80 ExiStation<sup>TM</sup>48 system (ExiPrep<sup>TM</sup>48 Dx & Exicycler<sup>TM</sup>96, BIONEER, Korea), in which the 81 test is processed automatically from RNA extraction to PCR detection and confirmation. The 82 SCVM has been developed for use with various other manufacturers' PCR instruments. The 83 limit of detection (LoD), cross-reactivity, and precision of the AccuPower® kits (SCVM and 84 NCVM) were evaluated with SARS-CoV-2 positive materials as well as commonly used 85 human clinical samples (sputum samples and nasopharyngeal swab (NPS)/oropharyngeal swab 86 (OPS) samples). In addition, the clinical performance of the AccuPower<sup>®</sup> kits was verified for 87 use in the NPS/OPS specimen pooling test and with saliva samples. 88

89

## 90 Materials and Methods

## 91 Primers and Probe Design

Primers and probes were designed to detect SARS-CoV-2 RNA according to two guidelines, the WHO Interim guideline and the KDCA (Korea Disease Control and Prevention Agency) guideline. The primers and probes target three different genes of SARS-CoV-2 (RdRP gene, N gene, and E gene). *In silico* analysis for inclusivity was conducted by comparing primers and probes for an alignment with all COVID-19 sequences (n=3037) in the GISAID database as of April 9th, 2020. The MUSCLE alignment was generated by multiple sequence alignment and viewed in Jalview. *In silico* analyses were performed against the updated

99 standard database (n= 1,060,413 May 31, 2021) of the National Center for Biotechnology
100 Information to confirm the current coverage of primers and probes. The coverage change of
101 primers and probes was not significant. The target genes and coverage of each primer or probe
102 are stated in Table 1.

103

Target Gene	Oligomer	Coverage (%)	Max. Coverage (%)	Current Coverage (%)
	Forward primer	99.97%		
E gene 1	Reverse primer	99.96%	100%	99.94%
	Probe	99.96%		
	Forward primer	99.99%		
F 2	Reverse Primer1	99.93%	1000/	99.94%
E gene2	Reverse Primer2	100%	100%	
	Probe	100%		
	Forward primer	99.99%		
RdRp gene 2-2	Reverse primer	99.98%	100%	99.89%
	Probe	99.98%		
	Forward primer	96.67%		
N gene	Reverse primer	99.40%	99.97%	95.06%
	Probe	99.89%		

## 104 Table 1. The target genes and coverage of primer and probe of the AccuPower<sup>®</sup> kits

105

## 106 AccuPower<sup>®</sup> Kits

107 AccuPower<sup>®</sup> kits contain specific primer, specific dual-labeled fluorogenic (TaqMan<sup>®</sup>)
 108 probe, DNA polymerase, reverse transcriptase, dNTPs, and stabilizer. Primers and fluorescent
 109 probes attach specific sequences, which distinctively appear in the SARS-CoV-2 gene.

TaqMan<sup>®</sup> probe contains the fluorescence in the 5' end and the quencher in the 3' end so the fluorescence is not released in the usual state. The fluorescence signal is emitted as the 5'-3' exonuclease in DNA polymerase detaches from the probe, while the fluorescence and the quencher detach during PCR.

The RNA presence can be detected by fluorescence signals. The NCVM is a freezedried premixed product for use only with the *ExiStation*<sup>TM</sup>48 system (*ExiPrep*<sup>TM</sup>48 Dx & *Exicycler*<sup>TM</sup>96). The SCVM is a master-mix product, which can be used with various PCR instruments. PCR reaction of *AccuPower*<sup>®</sup> kits was conducted according to each manufacturer's protocol.

119

## 120 Analytical Performance Evaluation

The LoD, cross-reactivity, and precision were analyzed using the AccuPlex<sup>™</sup> SARS-121 CoV-2 Verification Panel (Virus-Like Particles, SeraCare, USA) for the NCVM, and SARS-122 Related Coronavirus 2 (Isolate USA-WA1/2020) for the SCVM. The RNA of the SARS-CoV-123 2 Panel was extracted after dilution with E gene and SARS-CoV-2 gene negative NPS/OPS or 124 sputum matrix, then the RT-PCR process was performed. RNA extraction and PCR were 125 performed on the ExiStation<sup>TM</sup> 48 system. RNA extraction of the SARS-Related Coronavirus 126 2 was performed using the *ExiPrep*<sup>™</sup> 48 DX (BIONEER, Korea) after dilution of the NPS/OPS 127 128 or sputum matrix, following the manufacturer's instructions.

129

## 130 Limit of Detection

The LoD measurement was performed, following the CLSI guideline EP17-A2 (6).
The LoD for the E gene and the SARS-CoV-2 gene were determined by measuring the RNA
level in the AccuPlex<sup>™</sup> SARS-CoV-2 Verification Panel (Virus-Like Particles, SeraCare, USA)
using the NCVM, and the SARS-Related Coronavirus 2 (Isolate USA-WA1/2020) using the
SCVM.

The AccuPlex<sup>™</sup> SARS-CoV-2 Verification Panel were serially diluted to 6 136 concentration levels (240, 200, 160, 120, 80, 40 copies/mL) for the NCVM testing. Each 137 dilution was tested in total 40 replicates, 20 replicates per lot, 2 lots. The SARS-Related 138 Coronavirus 2 (Isolate USA-WA1/2020) also were serially diluted to 6 concentration levels (6, 139 5, 4, 3, 2, 1 copies/µL) for the SCVM testing. Each dilution was tested in total 60 replicates, 140 141 20 replicates per lot, 3 lots. Both LoD tests were performed on the *Exicycler*<sup>TM96</sup> (BIONEER, Korea) and determined using hit-rate analysis as the concentration at the lowest dilution that 142 143 can be detected with >95% probability.

144

## 145 **Cross-reactivity**

The cross-reactivity test was performed according to WHO EUL guidance (7) and Food and Drug Administration (FDA) guideline (8). The specificity of *AccuPower®* kits for SARS-CoV-2 detection was evaluated by *in silico* analysis followed by testing the SARS-CoV-2 control with respiratory disease-related viruses and bacteria genes (concentration above 1.0x10<sup>6</sup> copies/mL). Altogether, 29 respiratory disease-related microorganisms were tested using the NCVM and 38 were tested using the SCVM. The cross-reactivity test was performed using the *Exicycler*TM96.

153

## 154 **Precision**

The repeatability was tested according to the CLSI Guideline EP05-A3 (9) and EP15-A3 (10). The repeatability of the *AccuPower*<sup>®</sup> kits performance was evaluated by intra-assay and inter-assay variations at different concentrations of NPS/OPS, sputum, and saliva samples.

....

## 159 Ethics Statement and Sample Collection

Myongji Hospital Institutional Review Board (IRB) approved the use of surplus 160 clinical samples for the NPS/OPS specimen-pooling (IRB No.: MJH 2020-12-028) and 161 clinical performance evaluation (IRB No.: MJH 2020-12-029) tests. Kangwon National 162 University Hospital IRB approved the use of saliva and NPS/OPS samples for the clinical 163 performance testing of the AccuPower<sup>®</sup> kits (IRB No.: KNUH-2021-03-014), which were 164 165 either surplus samples or de-identified patient samples drawn after informed consent (Fig 1). RNA in the NPS/OPS and sputum samples was extracted using the *ExiPrep*<sup>TM</sup>48 Viral 166 DNA/RNA Kit (BIONEER, Korea) with the ExiPrep<sup>TM</sup>48 Dx instrument and the RNA of 167 saliva samples was extracted using the *ExiPrep*<sup>TM</sup>48 Fast Viral RNA Kit (BIONEER, Korea) 168 with the *ExiPrep*<sup>TM</sup>48 Dx instrument. Previously, it was determined whether each sample was 169 SARS-CoV-2 positive or negative by the confirmation test. 170

171

Fig 1. Summary of clinical specimens analyzed in this study. NPS, Nasopharyngeal Swab;
OPS, Oropharyngeal Swab.

174

## 175 Clinical Performance Evaluation Test

The clinical performance of *AccuPower*<sup>®</sup> kits was evaluated by comparing the PCR 176 result of each AccuPower<sup>®</sup> kit to that of the confirmation test with confirmed positive or 177 negative samples. A total of 343 sputum samples and 343 NPS/OPS samples were collected for 178 clinical performance evaluation. The distribution of the Ct value of positive samples was 179 180 described in Supplementary S1 Fig. At least 30 % of positive samples had Ct values within the cut-off Ct value - 10. The confirmation test was performed with the STANDARD<sup>™</sup> M nCoV 181 Real-Time Detection kit, the Q-Sens<sup>®</sup> COVID-19 Detection Kit V2 (CancerRop, Korea), or 182 the Allplex<sup>™</sup> 2019-nCoV Assay (Seegene, Korea) beforehand at the sample collection institute. 183 Presuming the result of the confirmation test was true, the clinical sensitivity and specificity of 184 AccuPower<sup>®</sup> kits were calculated. In addition, to validate the application of AccuPower<sup>®</sup> kits 185 as alternative diagnostic kits for SARS-CoV-2, the detection rate of confirmed positive and 186 negative samples was compared to samples tested using the *AccuPower*<sup>®</sup> kits and the reference 187 kit (STANDARD<sup>™</sup> M nCoV Real-Time Detection kit). STANDARD<sup>™</sup> M nCoV Real-Time 188 Detection kit is approved by the WHO and the FDA for SARS-CoV-2 detection for Emergency 189 Use Authorization (EUA) and officially approved the first kit by the Ministry of Food and Drug 190 Safety (MFDS), Korea. The RNA in samples was extracted using the *ExiPrep*<sup>™</sup>48 Viral 191 DNA/RNA Kit with the *ExiPrep*<sup>TM</sup>48 Dx instrument. PCR reaction was conducted using the 192 Exicvcler<sup>тм</sup>96. 193

194

## 195 Nasopharyngeal Swab and Oropharyngeal Swab Specimen

## **Pooling Test**

A 5-pool test on NPS/OPS samples was performed to evaluate the performance of the 197 AccuPower<sup>®</sup> kits on the pooled sample. A total of 180 samples (30 positive samples and 150 198 199 negative samples) were tested individually and in pools of 5 samples with the reference kit (STANDARD<sup>™</sup> M nCoV Real-Time Detection kit) and the AccuPower<sup>®</sup> kits. At least 25 % 200 of the positive samples had Ct values within the cut-off Ct range of 2~3. The 30 positive 201 pooled samples and 30 negative pooled samples were prepared. Experimental positive pools 202 were created using 80 µL from one SARS-CoV-2 positive specimen mixed with 4 negative 203 204 patient specimens (80 µL each) for a total volume of 400 µL. Experimental negative pools included 5 negative patient specimens (80 µL each). The RNA in pooled samples was 205 extracted using *ExiPrep*<sup>TM</sup>48 Viral DNA/RNA Kit with the *ExiPrep*<sup>TM</sup>48 Dx instrument. PCR 206 reaction was conducted using the *Exicvcler*<sup>TM</sup>96. 207

The AccuLoader<sup>™</sup> (BIONEER, Korea) which was designed to automatically load 208 samples into a reaction well was used to pool NPS/OPS specimens to reduce human error and 209 carry-over/cross-over contamination (Fig 2). A tablet PC connected to the AccuLoader™ 210 controls the instrument, which consists of a barcode reader, a contamination shield cover, and 211 212 a contamination prevention filter. The user inputs the sample loading positions and volumes into the PC, then, and after reading the 1D barcode attached to each sample collection tube, the 213 instrument directs the well-plate to automatically move to the proper position which prevents 214 sample from being loaded in the wrong well. A contamination shield cover protects other wells 215 from splashes that may occur during sample loading and a contamination prevention filter 216 minimizes cross-contamination from tip contact. For the pooling test, users input the number 217 of samples and the pooled volume, and the software calculated the required volume of each 218

sample in the pool.

220

Fig 2. NPS/OPS specimens pooling with *the*  $AccuLoader^{\mathsf{TM}}$ .  $AccuLoader^{\mathsf{TM}}$  recognizes the information of each sample by scanning the barcode on a sample tube, then guides the user to dispense samples in the correct well.

224

## 225 Clinical Performance of AccuPower<sup>®</sup> kits with Saliva Samples

The clinical performance of *AccuPower*<sup>®</sup> kits with saliva samples was evaluated by analyzing the correlation between the PCR results of saliva samples and that of NPS/OPS samples. Saliva and NPS/OPS samples were collected in pairs from each patient. Patients were in a variety of stages in COVID-19 from asymptomatic period to 22 days after symptom onset. Altogether, 47 positive and 40 negative saliva and NPS/OPS paired samples were collected and stored. The RNA was extracted using the *ExiPrep*<sup>TM</sup>48 Fast Viral RNA Kit with the *ExiPrep*<sup>TM</sup>48 DX instrument. PCR reaction was conducted using the *Exicycler*<sup>TM</sup>96.

Saliva samples were collected and stored using the Saliva Collection Kit (BIONEER,
Korea), which was developed to collect, transport, and preserve saliva specimens for extraction
of human genomic DNA, bacterial genomic DNA, and viral DNA/RNA for disease detection.
Collection kits were gently inverted 5 times after saliva collection to properly mix the saliva
and the preservation buffer.

238

## 239 Statistical Analysis

Statistical analyses were conducted with R Studio 1.3.1093. In addition, the 2x2 contingency-table method was used for analyzing sensitivity, specificity, agreement, and Cohen's kappa coefficient. Kendall's W test was used for analyzing the correlation between PCR results in saliva samples and those in NPS/OPS samples.

244

## 245 **Results**

## 246 Limit of Detection

- The LoD of NCVM was 120 copies/mL for the E gene (hit rate = 95%) and 120 copies/mL for the SARS-CoV-2 gene (hit rate = 95%) using the *ExiStation*<sup>TM</sup>48 System (*ExiPrep*TM48 Dx & *Exicycler*TM96). The LoD of SCVM was 2 copies/µL for the E gene (hit rate = 95%), 2 copies/µL for the SARS-CoV-2 gene (hit rate = 95%) using the *ExiCycler*<sup>TM</sup>96. (Table 2).
- 252

## 253 Table 2. Characteristic and PCR condition for LoD test of the AccuPower<sup>®</sup> kits

RT-PCR kit	Mix type	RNA extraction equipment	PCR equipment	Target genes	Limit of detection
AccuPower <sup>®</sup> COVID-19				E gene	E gene: 120 copies/mL
Multiplex Real-Time RT-PCR Kit	Premix Kit	Existation $^{\text{TM}}$ 48	Existation <sup>™</sup> 48	*SARS-CoV-2 gene	SARS-CoV-2 gene: 120 copies/mL
AccuPower <sup>®</sup> SARS-CoV-2		TM	TM	E gene	E gene: 2 copies/µL
Multiplex Real-Time RT- PCR Kit	Master mix	Exiprep <sup>134</sup> 8 DX	Exicycler <sup>™</sup> 96	*SARS-CoV-2 gene	SARS-CoV-2 gene: 2 copies/µL

254 \*SARS-CoV-2 gene: RdRp gene and N gene

255

## 256 Cross-reactivity

Based on *in silico* analysis, the designed primer and probe sequences were not expected to have a significant PCR amplification by other respiratory disease-related microorganisms, and this proved to be correct. The *AccuPower*<sup>®</sup> kits showed no positivity to

respiratory disease-related viruses or bacteria except E gene positivity on NATrol Coronavirus-260 SARS Stock (qualitative, NATSARS-ST / 2003-00592). Since NATrol Coronavirus-SARS 261 Stock originally contains the E gene, it was concluded that none of the AccuPower® kits 262 exhibited cross-reactions with other respiratory viruses or bacteria (Table 3). 263

264

#### No Organism No Organism 1 Human Influenza virus A H3N2 20 Parainfluenza virus 4a 2 Human Influenza virus A H1N1 21 Chlamydia pneumoniae Human Influenza virus B (Texas/6/11) 3 22 Haemophilus influenzae (Victoria) 4 Human Coronavirus 229E 23 Legionella pneumophila 5 Human Coronavirus NL63 Streptococcus pneumoniae 24 6 Human Coronavirus OC43 25 Streptococcus pyrogenes 7 Human Respiratory syncytial virus A Bordetella pertussis 26 8 Human Respiratory syncytial virus B 27 Mycoplasma pneumoniae Pooled Human nasal wash - to represent diverse 9 Human Rhinovirus 14 (type B) 28 microbial flora in the human respiratory tract NATtrol Coronavirus-SARS Stock (qualitative) 10 Human Metapneumovirus(hMPV) 29 (NATSARS-ST/ 2003-00592) Enterovirus 70 11 Human Adenovirus type 3 (type B) 30 12 Enterovirus 71 Coxsackievrus B5 31 13 Mycobacterium tuberculosis H37Rv Echovirus 25 32 MERS-CoV 14 33 Human Parachovirus 3 Human coronavirus HKU1 15 34 Mycobacterium fortuitum (HCOV-HKU1) 16 Adenovirus(71) 35 Mycobacterium intracell Parainfluenza virus 1 Mycobacterium gordonae 17 36

#### Table 3. List of pathogens tested for cross-reactivity 265

- 14 -

18	Parainfluenza virus 2	37	Mycobacterium chelonae
19	Parainfluenza virus 3	38	Pneumocystis jirovecii(PJP)

Cross reactivity was evaluated using both *in silico* analysis and by PCR test. Cross reactivity
of NCVM was tested with 29 pathogens (No.1 - 29). Cross-reactivity of SVCM was tested with
38 pathogens (No.1 - 38).

269

## 270 **Precision**

The repeatability of the *AccuPower*<sup>®</sup> kits was analyzed by comparing Ct values of the PCR result within runs, between runs, and between days in each matrix at each concentration. The standard deviation (SD) of Ct values in each condition was calculated. The SD result indicates no significant difference in Ct values for positive controls within-run, between-run, between-day, and total precision. (S1 Table).

276

## 277 Clinical Performance Evaluation Test

The clinical performance of the NCVM was evaluated by comparing it to the confirmation test. For sputum samples, the clinical sensitivity of NCVM was 97.50% (95% CI: 93.72% - 99.31%) and the clinical specificity was 98.36% (95% CI: 95.28% - 99.66%). For NPS/OPS samples, the clinical sensitivity the NCVM was 100.00% (95% CI: 97.72% -100.00%) and the clinical specificity was 98.91% (95% CI: 96.11% - 99.87%) (Table 4).

283

Table 4. Clinical sensitivity and specificity evaluation results for the *AccuPower*<sup>®</sup> kits in

### 285 Sputum or NPS/OPS specimens.

RT-PCR Kit	Specimen type	Ν	Sensitivity (%)	95% CI(%)	Specificity (%)	95% CI (%)
AccuPower <sup>®</sup>	Sputum	343	97.50	93.72 - 99.31	98.36	95.28 - 99.66
COVID-19						
Multiplex						
Real-Time RT-	NPS/OPS	343	100.00	97.72 - 100.00	98.91	96.11 - 99.87
PCR Kit						
AccuPower®	Sputum	343	98.75	95.56 - 99.85	99.45	96.99 - 99.99
SARS-CoV-2						
Multiplex Real-	NPS/OPS	343	98.75	95.56 - 99.85	98.91	96.11 - 99.87
Time RT-PCR Kit						

286

The correlation of the PCR result of the NCVM and that of the reference kit was also 287 288 evaluated. For sputum samples, the positive percentage agreement was 96.27% (95% CI: 92.07% - 98.62%), the negative percentage agreement was 98.90% (95% CI: 96.07% - 99.87%), the 289 290 total percentage agreement was 97.38% (95% CI: 95.08% - 98.79%), and the Cohen's kappa coefficient was 0.95. For NPS/OPS samples, the positive percentage agreement was 98.14% 291 (95% CI: 94.65% - 99.61%), the negative percentage agreement was 98.90% (95% CI: 96.07%) 292 - 99.87%), the total percentage agreement was 98.25% (95% CI: 96.23% - 99.36%), and the 293 Cohen's kappa coefficient was 0.97 (Table 5). 294

295

# Table 5. Clinical agreement evaluation results for the AccuPower<sup>®</sup> kits with STANDARD<sup>™</sup> M nCoV Real-Time Detection kit

RT-PCR Kit	Specimen type	Ν	PPA(%)	95% CI(%)	NPA (%)	95% CI (%)	Cohen's kappa

AccuPower®         Sputum         343         96.27         92.07 - 98.62         98.90         96.07 - 99.87         0.95           COVID-19         Multiplex Real-         Time RT-PCR         NPS/OPS         343         98.14         94.65 - 99.61         98.90         96.07 - 99.87         0.95           Kit         AccuPower®         Sputum         343         97.52         93.76 - 99.32         99.45         96.96 - 99.99         0.96           SARS-CoV-2         Multiplex Real-         Time RT-PCR         NPS/OPS         343         98.14         94.65 - 99.61         99.45         96.96 - 99.99         0.96           Kit         Sputum         343         97.52         93.76 - 99.32         99.45         96.96 - 99.99         0.96           Kit         Sputum         343         97.52         93.76 - 99.32         99.45         96.96 - 99.99         0.97           Kit         Kit         Sputum         343         98.14         94.65 - 99.61         99.45         96.96 - 99.99         0.97								
Multiplex Real- Time RT-PCR       NPS/OPS       343       98.14       94.65 - 99.61       98.90       96.07 - 99.87       0.97         Kit       AccuPower®       Sputum       343       97.52       93.76 - 99.32       99.45       96.96 - 99.99       0.96         SARS-CoV-2       Multiplex Real- Time RT-PCR       NPS/OPS       343       98.14       94.65 - 99.61       99.45       96.96 - 99.99       0.97	AccuPower <sup>®</sup>	Sputum	343	96.27	92.07 - 98.62	98.90	96.07 - 99.87	0.95
Time RT-PCR       NPS/OPS       343       98.14       94.65 - 99.61       98.90       96.07 - 99.87       0.97         Kit       AccuPower®       Sputum       343       97.52       93.76 - 99.32       99.45       96.96 - 99.99       0.96         SARS-CoV-2       Multiplex Real-       Subscript of the state       Subscript of the state       Subscript of the state       Output of the state       Subscript of the state       Subscrip	COVID-19							
Kit       AccuPower®       Sputum       343       97.52       93.76 - 99.32       99.45       96.96 - 99.99       0.96         SARS-CoV-2       Multiplex Real-       Time RT-PCR       NPS/OPS       343       98.14       94.65 - 99.61       99.45       96.96 - 99.99       0.97	Multiplex Real-							
AccuPower®       Sputum       343       97.52       93.76 - 99.32       99.45       96.96 - 99.99       0.96         SARS-CoV-2       Multiplex Real-       Time RT-PCR       NPS/OPS       343       98.14       94.65 - 99.61       99.45       96.96 - 99.99       0.97	Time RT-PCR	NPS/OPS	343	98.14	94.65 - 99.61	98.90	96.07 - 99.87	0.97
SARS-CoV-2         Multiplex Real-           Time RT-PCR         NPS/OPS         343         98.14         94.65 - 99.61         99.45         96.96 - 99.99         0.97	Kit							
SARS-CoV-2         Multiplex Real-           Time RT-PCR         NPS/OPS         343         98.14         94.65 - 99.61         99.45         96.96 - 99.99         0.97								
Multiplex Real-         Time RT-PCR         NPS/OPS         343         98.14         94.65 - 99.61         99.45         96.96 - 99.99         0.97	AccuPower®	Sputum	343	97.52	93.76 - 99.32	99.45	96.96 - 99.99	0.96
Time RT-PCR         NPS/OPS         343         98.14         94.65 - 99.61         99.45         96.96 - 99.99         0.97	SARS-CoV-2							
lime RI-PCR	Multiplex Real-							
Kit	Time RT-PCR	NPS/OPS	343	98.14	94.65 - 99.61	99.45	96.96 - 99.99	0.97
	Kit							

298 PPA, Positive Percentage Agreement; NPA, Negative Percentage Agreement

299

The clinical performance of the SCVM was evaluated by comparing it to the confirmation test. For sputum samples, the clinical sensitivity of the SCVM was 98.75% (95% CI: 95.56% - 99.85%) and the clinical specificity was 99.45% (95% CI: 96.99% - 99.99%). For NPS/OPS samples, the clinical sensitivity of the SCVM was 98.75% (95% CI: 95.56% -99.85%) and the clinical specificity was 98.91% (95% CI: 96.11% - 99.87%) (Table 4).

305 The correlation between results of the SCVM and that of the reference kit was evaluated. For sputum samples, the positive percentage agreement was 97.52% (95% CI: 93.76% 306 - 99.32%), the negative percentage agreement was 99.45% (95% CI: 96.96% - 99.99%), the 307 total percentage agreement was 98.25% (95% CI: 96.23% - 99.36%), and the Cohen's kappa 308 coefficient was 0.96. For NPS/OPS samples, the positive percentage agreement was 98.14% 309 (95% CI: 94.65% - 99.61%), the negative percentage agreement was 99.45% (95% CI: 96.96% 310 - 99.99%), the total percentage agreement was 98.54% (95% CI: 96.63% - 99.53%), and the 311 Cohen's kappa coefficient was 0.97 (Table 5). 312

The correlation of Ct values in target genes among NCVM, SCVM, and STANDARD<sup>TM</sup> M nCoV Real-Time Detection kit was analyzed by correlation analysis with the plot in R studio and showed significant correlations with coefficient of determination ( $R^2$ ) at  $\geq 0.97$  (S2 Fig). An analysis of Ct values was also performed using the ANOVA test with master mix kits (STANDARD<sup>TM</sup> M nCoV Real-Time Detection kit and SCVM). The ANOVA test showed no significant difference between SCVM and STANDARD<sup>TM</sup> M nCoV Real-Time Detection kit (P>0.05) (S3 Fig).

320

# Nasopharyngeal Swab and Oropharyngeal Swab Specimen Pooling Test

Pooled samples were prepared as described above (S2 Table). Samples were then 323 tested individually using the AccuPower<sup>®</sup> kits and the reference kit. The test showed 100% 324 positive and negative agreement of the AccuPower<sup>®</sup> kits with the reference kit. The clinical 325 performance of the AccuPower<sup>®</sup> kits was also tested using in 5-pooled samples and evaluated 326 by comparing the PCR results from the AccuPower® kits to that of the reference kit. For NCVM, 327 the positive percentage agreement was 93.30% (95% CI: 77.93% - 99.18%) and the negative 328 percentage agreement was 100.00% (95% CI: 88.43% - 100.00%) with the reference test of 329 pooled samples. 330

The positive and negative agreement between pooled samples and individual samples was also analyzed. For NCVM, the positive percentage agreement of pooled samples was 93.30% (95% CI: 77.93% - 99.18%) and the negative percentage agreement was 100.00% (95% CI: 88.43% - 100.00%), compared to individual samples. The average Ct value of pooled samples

was 1.65 higher than the average Ct value of individual samples in the E gene and 1.90 higher in the SARS-CoV-2 gene (Fig 3.A). The degree of association between the Ct value of individual samples and the Ct value of pooled samples was analyzed by regression analysis and expressed as y=0.887x+4.885,  $R^2=0.9700$  in the E gene and y=0.983x+2.375,  $R^2=0.9955$ in the SARS-CoV-2 gene (Fig 3.B).

For SCVM, the positive percentage agreement was of pooled samples 90.00% (95% 340 CI: 73.47% -97.89%) and the negative percentage agreement was 100.00% (95% CI: 88.43%) 341 - 100.00%) compared to the reference test. In addition, the positive percentage agreement was 342 90.00% (95% CI: 73.47% -97.89%) and the negative percentage agreement was 100.00% (95% 343 CI: 88.43% - 100.00%) in pooled sample, compared to individual samples. The average Ct 344 345 value of pooled samples was 0.94 higher than the average Ct value of individual samples in the E gene and 1.25 higher in the SARS-CoV-2 gene (Fig 3.A). The degree of association between 346 347 the Ct value of individual samples and the Ct value of pooled samples was analyzed by regression analysis and expressed as y=0.922x+2.841, R<sup>2</sup>=0.9716 in E gene and 348 y=1.017x+0.840, R<sup>2</sup>=0.9976 in SARS-CoV-2 gene (Fig 3.B). The results of the pooling tests 349 350 are described in Table 6. The disagreement between the PCR results of pooled samples and those of individual samples has occurred only in samples with low concentration (Ct>Cutoff 351 Ct - 3) of target genes (S3 Table). 352

353

## 354 Table 6. The pooling test evaluation results for the *AccuPower*<sup>®</sup> kits

Major discordance	Individual test (reference)				
	No.positive	No.negative	No.positive	No.negative	
	Individual test (NCVM)		Pool test	(NCVM)	

Positive	30	0	28	0
Negative	0	150	2	30
PPV (%)	100.00% (95% CI: 88.43% - 100.00%)		93.30% (95% CI: 77.93% - 99.18%)	
NPV (%)	100.00% (95% CI:	97.57% - 100.00%)	100.00% (95% CI	: 88.43% - 100.00%)
Accuracy (%)	100.	00%	96.6	57%
cohen's kappa (κ)	1.0	00	0.9	93

355

Major discordance	Individual test (reference)					
	No.positive	No.negative	No.positive	No.negative		
	Individual test (SCVM)		Pool test (SCVM)			
Positive	30	0	27	0		
Negative	0	150	3	30		
PPV (%)	100.00% (95% CI: 88.43% - 100.00%)		90.00% (95% CI: 73.47% -97.89%)			
NPV (%)	100.00% (95% CI: 97.57% - 100.00%) 100.00%		100.00% (95% CI: 88.43% - 100.00% 95.00%			
Accuracy (%)						
cohen's kappa (κ)	1.00		0.90			

356

# Fig 3. The comparison of Ct values in individual samples and pooled samples in NPS/OPS specimen pooling test (A) Ct values of individual and pooled samples in the *AccuPower*<sup>®</sup> kits. (B) The regression analysis with Ct values in individual samples and pooled samples in the *AccuPower*<sup>®</sup> kits.

361

## 362 Clinical Performance of AccuPower<sup>®</sup> kits with Saliva Samples

The clinical performance of the *AccuPower*<sup>®</sup> kits for use with saliva samples was evaluated by comparing the PCR results in saliva samples to those in NPS/OPS samples. The

- 20 -

365 Ct values of each *AccuPower<sup>®</sup>* kit using both kinds of samples from diverse stages of COVID366 19 are shown in Fig 4.A.

The PCR results of each AccuPower<sup>®</sup> kit used with each type of sample were verified 367 by comparison to the confirmation test. The NCVM PCR results for NPS/OPS samples showed 368 97.87% (95% CI: 88.71% - 99.95%) positive agreement, the 100.00% (95% CI: 91.19% -369 100.00%) negative agreement, and 98.85% (95% CI: 93.76% - 99.97%) total agreement with 370 a Cohen's kappa coefficient of 0.98, compared to the PCR results of the confirmation test for 371 NPS/OPS samples. The NCVM PCR results for saliva samples showed 100.00% (95% CI: 372 92.45% - 100.00%) positive agreement, 100.00% (95% CI: 91.19% - 100.00%) negative 373 374 agreement, and 100.00% (95% CI: 95.85% - 100.00%) total agreement with a Cohen's kappa 375 coefficient of 1.00, when compared to the PCR results of the confirmation test for NPS/OPS samples. The comparison of the NCVM PCR results between NPS/OPS samples and saliva 376 377 samples showed that 100.00% (95% CI: 92.29% - 100.00%) positive agreement, 97.56% (95% CI: 87.14% - 99.94%) negative agreement, and 98.85% (95% CI: 93.76% - 99.97%) total 378 agreement with Cohen's kappa coefficient of 0.98. 379

The SCVM PCR results for NPS/OPS samples showed 97.87% (95% CI: 88.71% -380 99.95%) positive agreement, 100.00% (95% CI: 91.19%- 100.00%) negative agreement, and 381 98.85% (95% CI: 93.76% - 99.97%) total agreement with a Cohen's kappa coefficient of 0.98, 382 compared to the PCR results of the confirmation test for NPS/OPS samples. The SCVM PCR 383 results for saliva samples showed 100.00% (95% CI: 92.45% - 100.00%) positive agreement, 384 100.00% (95% CI: 91.19% - 100.00%) negative agreement, and 100.00% (95% CI: 95.85% -385 100.00%) total agreement with a Cohen's kappa coefficient of 1.00, compared to the PCR 386 results of the confirmation test for NPS/OPS samples. The comparison of the SCVM PCR 387

388	results between NPS/OPS samples and saliva samples showed 100.00% (95% CI: 92.29% -
389	100.00%) positive agreement, 97.56% (95% CI: 87.14% - 99.94%) negative agreement, and
390	98.85% (95% CI: 93.76% - 99.97%) total agreement, with a Cohen's kappa coefficient of 0.98.
391	The results indicate the adequacy of the AccuPower <sup>®</sup> kits for the use with saliva samples (Table
392	7).


393	The scatter plots of Ct values in paired NPS/OPS and saliva specimens were analyzed
394	for each AccuPower <sup>®</sup> kit (Fig 4.B). The correlation of Ct values in paired NPS/OPS and saliva
395	specimens showed no significant difference in the E gene and the SARS-CoV-2 gene. Kendall's
396	W was over 0.5 in the E gene (W=0.639 for NCVM, 0.596 for SCVM) and the SARS-CoV-2
397	gene (W=0.613 for NCVM, 0.589 for SCVM), showing a high degree of agreement. In addition,
398	the association of Ct values in each type of sample with days from the onset of COVID-19 was
399	examined (Fig 4.C). Up to 10 days from the onset of COVID-19, Ct values of saliva samples
400	were lower than those of NPS/OPS samples. On the other hand, after 10 days from the onset
401	of COVID-19, Ct values of NPS/OPS samples were lower than those of saliva samples.

402

## 403 Table 7. Clinical performance evaluation results of the *AccuPower®* kits in saliva samples

	Specimen	Positive	Negative	PPV (%)	NPV (%)	Cohen's kappa
				(95% CI %)	(95% CI %)	
SD Kit	NPS/OPS	47	40	-	-	-
NCVM	NPS/OPS	46	41	97.87	100.00	0.98
				(88.71% - 99.95%)	(91.19% - 100.00%)	
	Saliva	47	40	100.00	100.00	1.00
				(92.45% - 100.00%)	(91.19% - 100.00%)	
	NPS/OPS-saliva agreement			100.00	97.56	0.98

				(92.29% - 100.00%)	(87.14% - 99.94%)	
	NPS/OPS	10	41	97.87	100.00	0.02
	NP5/OP5	46	41	(88.71% - 99.95%)	(91.19% - 100.00%)	0.98
SCVM	Saliva	47	40	100.00	100.00	1.00
				(92.45% - 100.00%)	(91.19% - 100.00%)	
	NPS/OPS-saliva agreement			100.00	97.56	0.98
				(92.29% - 100.00%)	(87.14% - 99.94%)	



405

#### Fig 4. Clinical performance of the *AccuPower<sup>®</sup>* kits in saliva and NPS/OPS samples (A) 406

Ct values of saliva and NPS/OPS samples from patients in various stages of COVID-19. (B) 407 Clinical performance comparison of the AccuPower<sup>®</sup> kits in saliva and NPS/OPS samples 408 shown in scatter plots. (C) Ct value comparison by boxplot among the NCVM, SCVM, and 409 STANDARD<sup>™</sup> M nCoV Real-Time Detection kit. ASX, Asymptomatic. 410

411

#### Discussion 412

The COVID-19 pandemic became the catalyst for the development of more rapid and 413 accurate detection methods for SARS-CoV-2 to better support the clinicians and front-line 414 healthcare professionals (11). While effective vaccines have been developed, the availability 415 of high-quality diagnostic methods remains essential (12). Many studies continue to target a 416 more efficient, reliable, and sensitive detection method for SARS-CoV-2. On the other hand, 417 multiplex RT-PCR viral RNA detection assays have been developed for fast and reliable SARS-418 CoV-2 detection (13-16). 419

The analytical performance of two AccuPower<sup>®</sup> kits (NCVM as the premix type and 420 SCVM as the master mix type) was evaluated. The NCVM was designed to be used on a closed 421 system (ExiStation<sup>TM</sup>48 system) to provide full automation and contamination-free and error-422 free results. The LoD of the NCVM was 120 copies/mL for the E gene and the SARS-CoV-2 423 gene as determined by the *ExiStation*<sup>TM</sup>48 system. On the other hand, the SCVM was designed 424 to be used on an open system compatible with other manufacturers' PCR instruments. The LoD 425 of the SCVM was 2 copies/ul for the E gene and the SARS-CoV-2 gene as determined by the 426 *Exicycler*<sup>TM</sup> 96. In addition, The LoD was determined by multiple alternative PCR instruments 427 (CFX96<sup>™</sup> Real-Time PCR Detection System (Bio-rad, USA), Applied Biosystems 7500 Fast 428 Real-time PCR Instrument system (Thermo Fisher Scientific, USA), QuantStudio<sup>™</sup>5 Real-429 Time PCR Instrument (Thermo Fisher Scientific), Exicycler™384 (BIONEER, Korea), 430 *Exicycler*<sup>TM96</sup> Fast (BIONEER, Korea)) and the results demonstrated comparable performance 431 (S4 Table). Cross-reactivity was tested with 29 respiratory disease-related viruses and bacteria 432 genes were performed for the NCVM, and with 38 for the SCVM, respectively. The results 433 showed that there was no detectable cross-reactivity in AccuPower® kits, Precision of the two 434 AccuPower<sup>®</sup> kits was evaluated and the results showed high within-run, between-run, between-435 day, and total precision. 436

This study provides the data to support the usability of the *AccuPower*<sup>®</sup> kits for the detection of SARS-CoV-2 RNA in sputum and NPS/OPS clinical samples as evidenced by equivalency with the confirmation test, which was performed in the collection institute beforehand, and with the reference kit (STANDARD<sup>TM</sup> M nCoV Real-Time Detection kit). Specifically, the results of the *AccuPower*<sup>®</sup> kits were validated with over 95% agreement with both the confirmation test and the reference kit. On the other hand, the NPS/OPS specimen

pooling test showed the PCR result of the pooled samples of 5 individuals had over 90% 443 agreement with the individual samples by the AccuPower<sup>®</sup> kits. The PCR results of the 444 AccuPower<sup>®</sup> kits in saliva samples showed over 95% positive and negative agreement with 445 those in the NPS/OPS samples, confirming the usability of the AccuPower<sup>®</sup> kits for the saliva 446 samples as well. In addition, the correlation between Ct values and days from the onset of 447 COVID-19 in both NPS/OPS and saliva samples indicates the saliva samples are more suitable 448 for detection up to 10 days from the onset of COVID-19 and the NPS/OPS samples are more 449 450 suitable for detection after 10 days from the onset of COVID-19 for SARS-CoV-2 detection. This result is consistent with the previous studies on the COVID-19 saliva samples (17). In 451 brief, the analytical and clinical performance of the AccuPower<sup>®</sup> kits showed they are as 452 effective in the SARS-CoV-2 detection kit as the current standard confirmation test including 453 the reference kit. 454

A previous study presented the LoD of *AccuPower*<sup>®</sup> kits without the appropriate 455 number of replications, using quantified specimens RNA for the test (18). On the contrary, in 456 this study, The LoD test was performed with 20 replicates, which is recommended in the CLSI 457 guideline, using SARS-CoV-2 verification panel and SARS-Related Coronavirus 2. In addition, 458 the clinical performance of each AccuPower<sup>®</sup> kit was tested with clinical samples of various Ct 459 and verified by comparing them to the performance of STANDARD<sup>™</sup> M nCoV Real-Time 460 Detection kit, which obtained WHO and FDA approval for emergency use and MFDS official 461 approval and showed high agreements (>95%). STANDARD<sup>TM</sup> M nCoV Real-Time Detection 462 kit showed higher clinical sensitivity with Allplex<sup>™</sup> 2019-nCoV Assay in a comparison study 463 (15). Also, the clinical performance evaluation of AccuPower® kits, assuming the result of 464 Allplex<sup>™</sup> 2019-nCoV Assay, which was one type of test in the confirmation test, as true, 465

indicated high sensitivity and specificity (>95%) (S5 Table). Thus, it may be suggested that
 *AccuPower*<sup>®</sup> kits have equivalent clinical sensitivity with Allplex<sup>™</sup> 2019-nCoV Assay.

In conclusion, this study describes the successful development of two multiplex real-468 time RT-PCR methods, NCVM and SCVM, for the diagnosis of SARS-CoV-2. Simultaneous 469 targeting of three viral genes (RdRP, N, and E) by the AccuPower<sup>®</sup> kits provides an accurate, 470 reliable, and easy-to-use SARS-CoV-2 detection test. The AccuPower<sup>®</sup> kits demonstrate the 471 analytical performance characteristics expected of a valid diagnostic assay. The clinical 472 performance of the AccuPower<sup>®</sup> kits was comparable to the gold standard confirmation test, 473 including the reference kit. In addition, the specimen pooling test with n=5 showed the ability 474 of the AccuPower<sup>®</sup> to process high volume samples cost-effectively for use as a surveillance 475 tool. The clinical performance test of AccuPower® kits in saliva samples demonstrated the 476 usability of the AccuPower<sup>®</sup> kits with saliva samples and the saliva samples being more 477 478 adequate than NPS/OPS samples for early detection (before 10 days from the onset of symptom) of COVID-19. The AccuPower<sup>®</sup> assay can be used for the fast and dependable detection of the 479 SARS-CoV-2 virus. 480

481

## 482 Acknowledgments

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI20C2557).

486

## 487 **References**

- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
  associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
- 490 2. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of
- 491 SARS-CoV-2. Nat Med. 2020;26(4):450-2.
- Kudo E, Israelow B, Vogels CBF, Lu P, Wyllie AL, Tokuyama M, et al. Detection of
  SARS-CoV-2 RNA by multiplex RT-qPCR. PLoS Biol. 2020;18(10):e3000867.
- 494 4. van Kasteren PB, van der Veer B, van den Brink S, Wijsman L, de Jonge J, van den
- Brandt A, et al. Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. J
  Clin Virol. 2020;128:104412.
- 497 5. Liu R, Fu A, Deng Z, Li Y, Liu T. Promising methods for detection of novel
  498 coronavirus SARS-CoV-2. View. 2020;1(1):e4.
- 6. CLSI. CLSI guideline EP17-A2. Evaluation of Detection Capability for Clinical
  Laboratory Measurement Procedures. Clinical and Laboratory Standards Institute 2nd edition.
  2012; Wayne, PA.
- 502 7. CLSI. CLSI guideline EP07-A2. Interference Testing in Clinical Chemistry. Clinical
  503 and Laboratory Standards Institute 2nd edition. 2005; Wayne, PA.
- FDA. Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency
   (Revised) Immediately in Effect Guidance for Clinical Laboratories, Commercial
   Manufacturers, and Food and Drug Administration Staff. 2020.
- 507 9. CLSI. CLSI guideline EP05-A3. Evaluating Quantitative Measurement Precision.
   508 Clinical and Laboratory Standards Institute 3rd edition. 2014; Wayne, PA.
- 509 10. CLSI. CLSI guideline EP15-A3. User Verification of Precision and Estimation.

510 Clinical and Laboratory Standards Institute 3rd edition. 2014; Wayne, PA.

Mannonen L, Kallio-Kokko H, Loginov R, Jaaskelainen A, Jokela P, Antikainen J, et
al. Comparison of Two Commercial Platforms and a Laboratory-Developed Test for Detection
of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA. J Mol Diagn.
2021;23(4):407-16.

- Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. Vaccine
  Breakthrough Infections with SARS-CoV-2 Variants. New England Journal of Medicine. 2021.
  Tombuloglu H, Sabit H, Al-Suhaimi E, Al Jindan R, Alkharsah KR. Development of
  multiplex real-time RT-PCR assay for the detection of SARS-CoV-2. PLoS One.
  2021;16(4):e0250942.
- 520 14. Zhen W, Berry GJ. Development of a New Multiplex Real-Time RT-PCR Assay for
  521 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Detection. J Mol Diagn.
  522 2020;22(12):1367-72.
- 523 15. Hur KH, Park K, Lim Y, Jeong YS, Sung H, Kim MN. Evaluation of Four Commercial
  524 Kits for SARS-CoV-2 Real-Time Reverse-Transcription Polymerase Chain Reaction Approved
- 525 by Emergency-Use-Authorization in Korea. Front Med (Lausanne). 2020;7:521.
- 526 16. Zhou Y, Pei F, Ji M, Wang L, Zhao H, Li H, et al. Sensitivity evaluation of 2019 novel
  527 coronavirus (SARS-CoV-2) RT-PCR detection kits and strategy to reduce false negative. PLoS
  528 One. 2020;15(11):e0241469.
- Teo AKJ, Choudhury Y, Tan IB, Cher CY, Chew SH, Wan ZY, et al. Saliva is more
  sensitive than nasopharyngeal or nasal swabs for diagnosis of asymptomatic and mild COVID19 infection. Scientific Reports. 2021;11(1):3134.
- 532 18. Freire-Paspuel B, Garcia-Bereguiain MA. Analytical and Clinical Evaluation of
  533 "AccuPower SARS-CoV-2 Multiplex RT-PCR kit (Bioneer, South Korea)" and "Allplex 2019-
  - 28 -

nCoV Assay (Seegene, South Korea)" for SARS-CoV-2 RT-PCR Diagnosis: Korean CDC EUA
as a Quality Control Proxy for Developing Countries. Front Cell Infect Microbiol.
2021;11:630552.

537


## 538 Supporting information

- S1 Fig. Ct value variation in collected clinical samples. Nashpharyngeal and Oropharyngeal
  swab specimens Ct distribution (Above). Sputum specimens Ct distribution (Below). \*SD:
  STANDARD<sup>TM</sup> M nCoV Real-Time Detection kit, Cutoff (Ct): 36 \*\*CancerRop: Q-Sens<sup>®</sup>
  COVID-19 Detection Kit V2, Cutoff (Ct): 40 \*\*\*Seegene: Allplex<sup>TM</sup> 2019-nCoV Assay,
  Cutoff (Ct): 40
- 544 S2 Fig. Correlation Analysis with plot among NCVM, SCVM, and STANDARD<sup>TM</sup> M

545 **nCoV Real-Time Detection kit.** Ct values among assays (NCVM, SCVM and STANDARD<sup>TM</sup>

- 546 M nCoV Real-Time Detection kit) showed high correlation with a Pearson  $R^2$  correlation 547 coefficient  $\geq 0.97$ .
- S3 Fig. Comparison between SCVM and STANDARD<sup>™</sup> M nCoV Real-Time Detection
  kit. Results of ANOVA test showed no significant difference between SCVM and
  STANDARD<sup>™</sup> M nCoV Real-Time Detection kit (p>0.05).
- 551 S1 Table. Precision evaluation results for the *AccuPower<sup>®</sup>* kits. Precision evaluation results
  552 of *AccuPower<sup>®</sup>* COVID-19 Multiplex Real-Time RT-PCR Kit and *AccuPower<sup>®</sup>* SARS-CoV553 2 Multiplex Real-Time RT-PCR Kit.
- 554 S2 Table. Individual samples and pooled samples in swab specimen pooling test.

- 555 S3 Table. The agreement between individual samples and pooled samples in the 556 AccuPower<sup>®</sup> kits.
- 557 **S4 Table. Limit of detection of SCVM in various PCR instruments.**
- 558 S5 Table. Clinical sensitivity and specificity evaluation results for the *AccuPower*<sup>®</sup> kits in
- 559 Sputum or NPS/OPS specimens, compared to Allplex<sup>™</sup> 2019-nCoV Assay.





## AccuLoader™


Multi-Well Sample Loader

Recognizing samples information and dispensing samples using *AccuLoader*<sup>™</sup>

.....

Step 2.

Anningh



1. Run the AccuLoader App

 Set up the app according to the condition you want to be dispense
 After setting, touch the start button Step 3.

 Recongnition of sample information through barcode scanner
 Dispense sample into wells guided by AccuLoader

